Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706H in Advanced Solid Tumors
NCT06047431Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 1, open-label, single-arm trial of iparomlimab and tuvonralimab in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoint: Minimum Serum Drug Concentration. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06047431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06047431.